4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

– Business combination transaction with OTR Acquisition Corp., a special purpose acquisition company, completed – – Combined company Comera Life Sciences Holdings, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "CMRA" – Comera Life Sciences Holdings, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))) (referred herein as "OTR"), a publicly traded special purpose acquisition company (SPAC). Comera Life Sciences Holdings, Inc., the resulting comb

Comera Life Sciences, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it has entered into a research collaboration with a top 10 global pharmaceutical company and developer of medicines across oncology, hematology and immunology and other therapeutic areas. Under the terms of the agreement, Comera will utilize its proprietary SQore™ formulation platform to develop a subcutaneous formulation of the partner's currently marketed medicine. "Our second announced collaboration this year is a critical milestone in our long-term strategy to partner with top-tier pharma c

Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that Robert P. Mahoney, Ph.D., Chief Scientific Officer, will present at the PEGS Boston Conference & Expo, being held May 2-6, 2022, in-person. Dr. Mahoney will discuss Comera's lead, patented caffeine-based excipient, which significantly reduced the viscosity of prominent monoclonal antibodies without affecting their stability or biologic activity in a recent peer-reviewed study.1 The presentation details are as follows: Title: Viscosity Reducing Excipients for Highly Concentrated Antibody Formulations Time: May 4, 202

Today, Comera Life Sciences, Inc. ("Comera" or the "Company") and Intas Pharmaceuticals Ltd. ("Intas") announced a research collaboration to develop a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220418005526/en/ Under the terms of the partnership agreement, Comera will develop a differentiated formulation of an Intas product using Comera's innovative proprietary SQore™ formulation platform. Intas will initially provide research funding with the option to acquire global rights to the formulation through an exclusive license w

Special meeting of OTR stockholders scheduled for May 10, 2022 Comera Life Sciences, Inc. ("Comera"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (NASDAQ:OTRA) ("OTR"), a publicly traded special purpose acquisition company (SPAC), today announced that the Securities and Exchange Commission ("SEC") has declared the Registration Statement on Form S-4 filed in connection with the proposed business combination between the two companies, to be effective. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220418005109/en/ A special

Investor Call Rescheduled to Tuesday, Feb. 8 at 8:30 a.m. EST to Discuss Combination between Comera Life Sciences, Inc. and OTR Acquisition Corp. OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))), a publicly traded special purpose acquisition company (SPAC), today announced the confidential submission with the U.S. Securities and Exchange Commission ("SEC") of a draft registration statement on Form S-4 (the "Registration Statement") relating to its previously announced proposed business combination with Comera Life Sciences, Inc. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220203006027/en/ In addition, the investor call

Comera Life Sciences is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience This transaction is expected to enable further investment in a compassionate new era in medicine by applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms and thereby give patients greater flexibility in their care Combined company to have an implied initial equity value of approximately $258.4 million translating into an enterprise value of approximately $151.3 million, with the proposed business combination expected to provide approximately $107 million in g

SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G - OTR Acquisition Corp. (0001821318) (Subject)

15-12B - OTR Acquisition Corp. (0001821318) (Filer)

8-K - OTR Acquisition Corp. (0001821318) (Filer)

25-NSE - OTR Acquisition Corp. (0001821318) (Subject)

425 - OTR Acquisition Corp. (0001821318) (Subject)

8-K - OTR Acquisition Corp. (0001821318) (Filer)

425 - OTR Acquisition Corp. (0001821318) (Subject)

8-K - OTR Acquisition Corp. (0001821318) (Filer)

425 - OTR Acquisition Corp. (0001821318) (Subject)

8-K - OTR Acquisition Corp. (0001821318) (Filer)

10-Q - OTR Acquisition Corp. (0001821318) (Filer)

Gainers NeuroMetrix, Inc. (NASDAQ:NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia. VivoPower International PLC (NASDAQ:VVPR) gained 46.3% to close at $1.58. NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) surged 29.6% to close at $0.7905. The FDA recently reviewed NeuroOne Medical Technologies appeal for 510(k) clearance for its Evo sEEG Electrode for less than 30-day use. BIT Mining Limited (NYSE:BTCM) rose 28.1% to settle at $2.10. Pop Culture Group Co., Ltd (NASDAQ:CPOP) gained 27.6% to close at $1.11.

Gainers NeuroMetrix, Inc. (NASDAQ:NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia. Grab Holdings Limited (NASDAQ:GRAB) gained 26.1% to $3.1902 after reporting Q1 results. SIGA Technologies, Inc. (NASDAQ:SIGA) shares gained 19.9% to $8.86 after the company announced the FDA approved the intravenous formulation of TPOXX for the treatment of smallpox. Zealand Pharma A/S (NASDAQ:ZEAL) jumped 17.3% to $13.73 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric patients with congenital hyperinsulin

Gainers Bright Green Corp. (NASDAQ:BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to list on a major U.S. stock exchange. Decisionpoint Systems, Inc. (NYSE:DPSI) shares climbed 70.9% to close at $8.15 on Wednesday. DecisionPoint Systems recently reported first-quarter FY22 revenue growth of 22.7% year-on-year to $19.7 million. Troika Media Group, Inc. (NASDAQ:TRKA) gained 52.1% to settle at $0.5780. Armstrong Flooring, Inc. (NYSE:AFI) climbed 46% to settle at $0.43 after receiving approval for additional financing. Magenta Therapeutics, Inc. (NASDAQ:MGTA) surged 32.2% to c

Gainers Decisionpoint Systems, Inc. (NYSE:DPSI) shares jumped 83.2% to $8.74. DecisionPoint Systems recently reported first-quarter FY22 revenue growth of 22.7% year-on-year to $19.7 million. Armstrong Flooring, Inc. (NYSE:AFI) jumped 30.6% to $0.3846 after receiving approval for additional financing. Verb Technology Company, Inc.. (NASDAQ:VERB) rose 24% to $0.5278 after jumping around 30% on Tuesday. DLocal Limited (NASDAQ:DLO) gained 21.4% to $23.37 after the company reported better-than-expected Q1 sales results. Bright Green Corp. (NASDAQ:BGXX) rose 20.2% to $30.37. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to lis

OTR Acquisition Corp (NASDAQ:OTRA) shares are trading higher Wednesday after the company filed a Form 8-K with the U.S. Securities and Exchange Commision. The move appears to be related to the high number of investors who opted for redemptions. According to the filing, holders of an aggregate of 9,769,363 shares of the company's stock have redeemed their shares in connection with the proposed business combination with Comera Life Sciences. There were 10,447,350 shares in total before redemptions. Only 677,987 shares were subject to redemption but not redeemed. Special purpose acquisition companies, or SPACs, often have redemption rights, which give investors the right to sell their shares

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 400 points on Wednesday. Following the market opening Wednesday, the Dow traded down 1.42% to 32,191.77 while the NASDAQ fell 1.99% to 11,746.34. The S&P also fell, dropping, 1.76% to 4,017.01. Also check this: Executives Buy Around $1.6M Of 4 Penny Stocks Leading and Lagging Sectors Utilities shares fell by just 0.2% on Wednesday. Meanwhile, top gainers in the sector included Huaneng Power International, Inc. (NYSE:HNP), up 6% and Hawaiian Electric Industries, Inc. (NYSE:HE) up 3%. In trading on Wednesday, consumer discretionary shares dipped 3.4%. Top Headline Target Corporation (NYSE:TGT) reported

Today's 5 Stock Ideas: Twitter (TWTR) - Shares fell as much as 27% in pre-market action following a tweet from Elon Musk that said his deal for Twitter was "temporarily on hold." A couple hours later, Musk tweeted again and said he was still committed to the deal. While Twitter shares rebounded to over the $40 level following the second tweet, the stock was still down about 12% ahead of the open. OTR Acquisition Corp. (OTRA) - A special purpose acquisition corporation (SPAC) redemption play for Friday and likely next week. A tweet highlighted "shareholders approved Comera Life Sciences deal, 10.3 million shares (98.4%) redeemed, leaving only 168k shares remaining." Benzinga writ

Gainers OTR Acquisition Corp. (NASDAQ:OTRA) rose 88.7% to $18.21 in pre-market trading after filing on Thursday showed shareholders approved merger with Comera Life Sciences. Calithera Biosciences, Inc. (NASDAQ:CALA) rose 46.3% to $0.2358 in pre-market trading. The company recently reported a net loss of $13.8 million for the three months ended March 31, 2022. Affirm Holdings, Inc. (NASDAQ:AFRM) shares rose 31.2% to $23.66 in pre-market trading after the company reported upbeat results for its third quarter and raised its revenue forecast for the fiscal year. The company also announced a multi-year extension of its partnership in the U.S. with Shopify. Molecular Partners AG (NASDAQ:MOL